Clinical Trial

Safety Shot Spins Off Caring Brands Business with Plans to Issue a Dividend to Shareholders

The Company is Divesting its Wellness Unit to Create Value for Shareholders and to Focus on Commercialization of its Safety…

1 year ago

Coronado Research announce appointment of Gail Kniveton to Chief Talent Officer role

LONDON, Sept. 26, 2024 /PRNewswire/ -- Coronado Research announced today that Gail Kniveton has been appointed as Chief Talent Officer.…

1 year ago

Rovia Clinical Research Launches as Parent Company to East Coast Institute for Research, Universal Axon Clinical Research, and IMIC Inc. Clinical Research Center

JACKSONVILLE, Fla., Sept. 26, 2024 /PRNewswire/ -- Rovia Clinical Research is excited to announce the creation of its clinical research…

1 year ago

LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH

MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore,…

1 year ago

Stemtech Sets Strategic Directions and Expands Into $303 Billion Pet Health Market, Boosted by Increased Demand For Anti-Aging Innovations

NAPLES, FL / ACCESSWIRE / September 26, 2024 / STEMTECH CORPORATION, ("STEK") Stemtech Corporation, a pioneer in the health and…

1 year ago

Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF)…

1 year ago

International Myeloma Foundation to Hold First Latin American Myeloma Network Summit in Brazil on September 28

The inaugural IMF Latin American Myeloma Network Summit will take place on Saturday, September 28, after the International Myeloma Society…

1 year ago

Interim results for the six months ended June 30, 2024

September 26, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2024…

1 year ago

Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

1 year ago